Current and emerging somatic treatment strategies in psychotic major depression

References

• Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. Am. J. Psych. 159(11), 1855–1861(2002).
   PubMed Web of Science ®Google Scholar
• Coryell W. The treatment of psychotic depression. J. Clin. Psych. 59(Suppl. 1), 22–27, discussion 9–8 (1998).
   Google Scholar
• Hill SK, Keshavan MS, Thase ME, Sweeney JA. Neuropsychological dysfunction in antipsychotic-naive first-episode unipolar psychotic depression. Am. J. Psych. 161(6), 996–1003 (2004).
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Spiker DG. Refractory depression: prediction of non-response by clinical indicators. J. Clin. Psych. 42(8), 307–312 (1981).
   Google Scholar
• Spiker DG, Weiss JC, Dealy RS et al. The pharmacological treatment of delusional depression. Am. J. Psych. 142(4), 430–436 (1985).
   PubMed Web of Science ®Google Scholar
• Wijkstra J, Lijmer J, Balk F, Geddes J, Nolen W. Pharmacological treatment for psychotic depression. Cochrane Database Syst. Rev. (4), CD004044 (2005).
   PubMedGoogle Scholar
• Swartz HA, Frank E, Shear MK, Thase ME, Fleming MA, Scott J. A pilot study of brief interpersonal psychotherapy for depression among women. Psychiatr. Serv. 55 (4), 448–450 (2004).
   PubMed Web of Science ®Google Scholar
• Klein DN, Santiago NJ, Vivian D et al. Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. J. Consult. Clin. Psychol. 72(4), 681–688 (2004).
   PubMed Web of Science ®Google Scholar
• Wheeler Vega JA, Mortimer AM, Tyson PJ. Somatic treatment of psychotic depression: review and recommendations for practice. J. Clin. Psychopharmacol. 20(5), 504–519 (2000).
   PubMedGoogle Scholar
• Schatzberg AF. New approaches to managing psychotic depression. J. Clin. Psych. 64(Suppl. 1), 19–23 (2003).
   Google Scholar
• Gatti F, Bellini L, Gasperini M, Perez J, Zanardi R, Smeraldi E. Fluvoxamine alone in the treatment of delusional depression. Am. J. Psych. 153(3), 414–416 (1996).
   PubMed Web of Science ®Google Scholar
• Anton RF, Sexauer JD. Efficacy of amoxapine in psychotic depression. Am. J. Psych. 140(10), 1344–1347 (1983).
   PubMedGoogle Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin re-uptake inhibitors. Br. J. Psych. 178, 234–241 (2001).
   PubMed Web of Science ®Google Scholar
• Dannon PN, Lowengrub K, Iancu I, Kotler M. Paroxetine in panic disorder: clinical management and long-term follow-up. Expert Rev. Neurother. 4(2), 191–198 (2004).
   PubMedGoogle Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: role of human cytochromes P450. J. Clin. Psych. 59 (Suppl. 15), 19–27 (1998).
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin re-uptake inhibitors in major depression. J. Clin. Psych. 60(4), 256–259 (1999).
   Google Scholar
• Thase ME. What role do atypical antipsychotic drugs have in treatment-resistant depression? J. Clin. Psych. 63(2), 95–103 (2002).
   Google Scholar
• Rothschild AJ, Williamson DJ, Tohen MF et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J. Clin. Psychopharmacol. 24(4), 365–373 (2004).
   PubMed Web of Science ®Google Scholar
• Konig F, von Hippel C, Petersdorff T, Neuhoffer-Weiss M, Wolfersdorf M, Kaschka WP. First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression. Neuropsychobiology 43(3), 170–174 (2001).
   PubMedGoogle Scholar
• Matthews JD, Bottonari KA, Polania LM et al. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J. Clin. Psych. 63(12), 1164–1170 (2002).
   Web of Science ®Google Scholar
• Petrides G, Fink M, Husain MM et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J. Ect. 17(4), 244–253 (2001).
   PubMed Web of Science ®Google Scholar
• O’Connor MK, Knapp R, Husain M et al. The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. report. Am. J. Geriatr. Psych. 9(4), 382–390 (2001).
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Prudic J, Devanand DP et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch. Gen. Psych. 57(5), 425–434 (2000).
   PubMed Web of Science ®Google Scholar
• US Department. Health Human Services AfHCPaR. Clinical Practice Guideline Number 5. In: Depression in Primary Care. MD: AHCPR Publication, WA, USA (1993).
   Google Scholar
• Nelson JC, Mazure CM. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am. J. Psych. 143(3), 363–366 (1986).
   PubMed Web of Science ®Google Scholar
• Thase ME, Ninan PT. New goals in the treatment of depression: moving toward recovery. Psychopharmacol. Bull. 36(Suppl. 2), 24–35 (2002).
   PubMedGoogle Scholar
• Reimherr FW, Amsterdam JD, Quitkin FM et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am. J. Psych. 155(9), 1247-1253 (1998).
   PubMed Web of Science ®Google Scholar
• Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J. Biol. Psych. 3(2), 69–86 (2002).
   PubMedGoogle Scholar
• Rothschild AJ, Duval SE. How long should patients with psychotic depression stay on the antipsychotic medication? J. Clin. Psych. 64(4), 390–396 (2003).
   Google Scholar
• Muller-Oerlinghausen B, Ahrens B, Grof E et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr. Scand. 86(3), 218–222 (1992).
   PubMedGoogle Scholar
• Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br. J. Psych. 162, 634–640 (1993).
   PubMed Web of Science ®Google Scholar
• Coryell W. Augmentation strategies for inadequate antidepressant response: a review of placebo-controlled studies. Ann. Clin. Psych. 12(3), 141–146 (2000).
   PubMedGoogle Scholar
• Faedda GL, Tondo L, Baldessarini RJ. Lithium discontinuation: uncovering latent bipolar disorder? Am. J. Psych. 158(8), 1337–1339 (2001).
   PubMedGoogle Scholar
• Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biol. Psych. 53(8), 680–690 (2003).
   PubMed Web of Science ®Google Scholar
• Husain MM, Rush AJ, Fink M et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J. Clin. Psych. 65(4), 485–491 (2004).
   Google Scholar
• Sackeim HA, Haskett RF, Mulsant BH et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 285(10), 1299–1307 (2001).
   PubMed Web of Science ®Google Scholar
• Andrade C, Kurinji S. Continuation and maintenance ECT: a review of recent research. J. Ect. 18(3), 149–158 (2002).
   PubMed Web of Science ®Google Scholar
• George MS, Wassermann EM, Williams WA et al. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport 6(14), 1853–1856 (1995).
   PubMed Web of Science ®Google Scholar
• Grunhaus L, Dannon PN, Schreiber S et al. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. Biol. Psych. 47(4), 314–324 (2000).
   PubMed Web of Science ®Google Scholar
• Dannon PN, Grunhaus L. Repetitive transcranial magnetic stimulation is effective following repeated courses in the treatment of major depressive disorder – a case report. Hum. Psychopharmacol. 18(4), 313–315 (2003).
   PubMedGoogle Scholar
• Grunhaus L, Schreiber S, Dolberg OT, Polak D, Dannon PN. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol. Psych. 53(4), 324–331 (2003).
   PubMed Web of Science ®Google Scholar
• Avery DH, Holtzheimeriii PE, Fawaz W et al. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol. Psych. (2005) (Epub ahead of print).
   PubMedGoogle Scholar
• Loo CK, Mitchell PB. A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy. J. Affect. Disord. 88(3), 255–267 (2005).
   PubMed Web of Science ®Google Scholar
• George MS, Sackeim HA, Marangell LB et al. Vagus nerve stimulation. A potential therapy for resistant depression? Psychiatr. Clin. North Am. 23(4), 757–783 (2000).
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Rush AJ, George MS et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 25(5), 713–728 (2001).
   PubMed Web of Science ®Google Scholar
• Chae JH, Nahas Z, Lomarev M et al. A review of functional neuroimaging studies of vagus nerve stimulation (VNS). J. Psychiatr. Res. 37(6), 443–455 (2003).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Marangell LB, Sackeim HA et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol. Psych. 58(5), 347–354 (2005).
   PubMed Web of Science ®Google Scholar
• Rush AJ, George MS, Sackeim HA et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol. Psych.47(4), 276–286 (2000).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Sackeim HA, Marangell LB et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol. Psych. 58(5), 355–363 (2005).
   PubMed Web of Science ®Google Scholar
• George MS, Rush AJ, Marangell LB et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol. Psych. 58(5), 364–373 (2005).
   PubMed Web of Science ®Google Scholar
• Kopell BH, Greenberg B, Rezai AR. Deep brain stimulation for psychiatric disorders. J. Clin. Neurophysiol. 21(1), 51–67 (2004).
   PubMed Web of Science ®Google Scholar
• Velasco F, Velasco M, Jimenez F, Velasco AL, Salin-Pascual R. Neurobiological background for performing surgical intervention in the inferior thalamic peduncle for treatment of major depression disorders. Neurosurgery 57(3), 439–448 (2005).
   PubMed Web of Science ®Google Scholar
• Jimenez F, Velasco F, Salin-Pascual R et al. A patient with a resistant major depression disorder treated with deep brain stimulation in the inferior thalamic peduncle. Neurosurgery 57(3), 585–593 (2005).
   PubMed Web of Science ®Google Scholar
• Mayberg HS, Lozano AM, Voon V et al. Deep brain stimulation for treatment-resistant depression. Neurone 45(5), 651–660 (2005).
   PubMed Web of Science ®Google Scholar
• Lisanby SH, Morales O, Payne N et al. New developments in electroconvulsive therapy and magnetic seizure therapy. CNS Spectr. 8(7), 529–536 (2003).
   PubMed Web of Science ®Google Scholar
• Lisanby SH, Luber B, Schlaepfer TE, Sackeim HA. Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology 28(10), 1852–1865 (2003).
   PubMed Web of Science ®Google Scholar
• Schatzberg AF, Rothschild AJ. The roles of glucocorticoid and dopaminergic systems in delusional (psychotic) depression. Ann. NY Acad. Sci. 537, 462–471 (1988).
   PubMed Web of Science ®Google Scholar
• Belanoff JK, Rothschild, AJ, Cassidy F. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol. Psych. 52, 386–392 (2001).
   Google Scholar
• Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. 21(5), 516–521 (2001).
   PubMed Web of Science ®Google Scholar
• Simpson GM, El Sheshai A, Loza N et al. An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. J. Clin. Psych. 66(5), 598–602 (2005).
   Google Scholar
• Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology (2005) (Epub ahead of print).
   PubMedGoogle Scholar